Beisol Pharma Poederlee: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Beisol Pharma Poederlee
Largest movements
- Receivables within one year -€5,787
down €5,787 (-19.2%), from €30,118 to €24,331
of which Trade receivables: -€8,340
- Trade debts -€10,500
no longer reported in 2026 (was €10,500)
- Profit (loss) carried forward +€7,573
up €7,573 (+9.9%), from -€76,564 to -€68,991
- Other debts -€3,059
down €3,059 (-1.9%), from €162,092 to €159,033
- Gross operating margin -€1,595
down €1,595 (-16.6%), from €9,635 to €8,040
- Purchases and services +€1,595
up €1,595 (+22.6%), from €7,045 to €8,640
From the 2025 result to the 2026 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2025 and 2026 balance sheets and the 2026 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2025 | 2026 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €105,600 | €99,614 | -€5,986 | -5.7% |
| Current assets | 29/58 | €105,600 | €99,614 | -€5,986 | -5.7% |
| Stocks and contracts in progress | 3 | €75,205 | €75,205 | = | 0.0% |
| Stocks | 30/36 | €75,205 | €75,205 | = | 0.0% |
| Amounts receivable within one year | 40/41 | €30,118 | €24,331 | -€5,787 | -19.2% |
| Trade receivables | 40 | €29,190 | €20,850 | -€8,340 | -28.6% |
| Other amounts receivable | 41 | €928 | €3,481 | +€2,553 | +275% |
| Cash at bank and in hand | 54/58 | €277 | €78 | -€199 | -71.8% |
| Total equity and liabilities | 10/49 | €105,600 | €99,614 | -€5,986 | -5.7% |
| Equity | 10/15 | -€66,992 | -€59,419 | +€7,573 | +11.3% |
| Contributions | 10/11 | €6,200 | €6,200 | = | 0.0% |
| Capital | 10 | €6,200 | €6,200 | = | 0.0% |
| Issued capital | 100 | €18,600 | €18,600 | = | 0.0% |
| Uncalled capital | 101 | €12,400 | €12,400 | = | 0.0% |
| Reserves | 13 | €3,372 | €3,372 | = | 0.0% |
| Non-distributable reserves | 130/1 | €169 | €169 | = | 0.0% |
| Legal reserve | 130 | €169 | €169 | = | 0.0% |
| Distributable reserves | 133 | €3,203 | €3,203 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€76,564 | -€68,991 | +€7,573 | +9.9% |
| Amounts payable | 17/49 | €172,592 | €159,033 | -€13,559 | -7.9% |
| Amounts payable within one year | 42/48 | €172,592 | €159,033 | -€13,559 | -7.9% |
| Trade debts | 44 | €10,500 | - | -€10,500 | |
| Suppliers | 440/4 | €10,500 | - | -€10,500 | |
| Other amounts payable | 47/48 | €162,092 | €159,033 | -€3,059 | -1.9% |
| Turnover | 70 | €16,680 | €16,680 | = | 0.0% |
| Goods, raw materials, services and sundry goods | 60/61 | €7,045 | €8,640 | +€1,595 | +22.6% |
| Other operating charges | 640/8 | €387 | €411 | +€24 | +6.2% |
| Gross operating margin | 9900 | €9,635 | €8,040 | -€1,595 | -16.6% |
| Operating profit (loss) | 9901 | €9,248 | €7,629 | -€1,619 | -17.5% |
| Financial charges | 65/66B | €30 | €56 | +€26 | +86.7% |
| Recurring financial charges | 65 | €30 | €56 | +€26 | +86.7% |
| Profit (loss) for the period before taxes | 9903 | €9,218 | €7,573 | -€1,645 | -17.8% |
| Profit (loss) for the period | 9904 | €9,218 | €7,573 | -€1,645 | -17.8% |
| Profit (loss) for the period to be appropriated | 9905 | €9,218 | €7,573 | -€1,645 | -17.8% |
Source: filed annual accounts (NBB), financial years ended 31 March 2025 and 31 March 2026. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 28 October 2026 via checked.be.